RecruitingPhase 2NCT06851559
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
Studying Primary eosinophilic gastrointestinal disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Phathom Pharmaceuticals, Inc.
- Principal Investigator
- Medical DirectorPhathom Pharmaceuticals
- Intervention
- Vonoprazan(drug)
- Enrollment
- 80 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (30)
- Preferred Research Partners, Inc, Little Rock, Arkansas, United States
- GW Research, Inc, Chula Vista, California, United States
- Southern California Research Institute Medical Group, Los Angeles, California, United States
- Rocky Mountain Gastroenterology, Lakewood, Colorado, United States
- Western States Clinical Research, Inc., Wheat Ridge, Colorado, United States
- Connecticut Clinical Research Institute, Bristol, Connecticut, United States
- Nature Coast Clinical Research, Inverness, Florida, United States
- Encore Borland-Groover Clinical Research, Jacksonville, Florida, United States
- International Center for Research, Tampa, Florida, United States
- Gastroenterology Associates of Central Georgia, LLC, Macon, Georgia, United States
- Treasure Valley Medical Research, Boise, Idaho, United States
- Grand Teton Research Group, Idaho Falls, Idaho, United States
- Northwestern Medicine Digestive Health Center, Chicago, Illinois, United States
- GI Alliance - Gurnee, Gurnee, Illinois, United States
- Combined Gastro, LLC, Lafayette, Louisiana, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06851559 on ClinicalTrials.govOther trials for Primary eosinophilic gastrointestinal disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06817213Patient-Centered Decision Support for Eosinophilic EsophagitisUniversity of Michigan
- RECRUITINGNCT06695897A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in GermanySanofi
- ACTIVE NOT RECRUITINGPHASE4NCT06352073Dupilumab for Eosinophilic Esophagitis With Severe StricturesUniversity of North Carolina, Chapel Hill
- RECRUITINGNANCT06381219Pediatric Eosinophilic Esophagitis (pedEoE): Effect of Allergen Heat Denaturation on EoE Remission: a Pilot TrialUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGNCT06991881Eosinophilic Esophagitis: Towards Improved ManagementOslo University Hospital
- RECRUITINGNANCT06501274Capsule Sponge Study in Eosinophilic OesophagitisEast and North Hertfordshire NHS Trust
- RECRUITINGNANCT05730933An Intervention Study to Improve Therapeutic Compliance in Adult Patients With Eosinophilic Esophagitis.Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- RECRUITINGPHASE1, PHASE2NCT05608681A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).Eupraxia Pharmaceuticals Inc.
See all trials for Primary eosinophilic gastrointestinal disease →